Six months after launching, then raising $130 million in two financing rounds, Adagio Therapeutics is heading into the clinic with an antibody that has shown promise against not only COVID-19 but also other coronaviruses, including SARS-CoV-1 (SARS-CoV) and MERS.
Adagio, a spinout of Adimab launched in July, filed November 30 for an IND with the FDA for ADG20. The antibody was engineered to confer a longer duration of protection than its precursor ADG2 by extending the antibody’s serum half-life.
“We expect to be in the clinic before the end of the year,” co-founder . . .